Welcome to our dedicated page for Aeluma SEC filings (Ticker: ALMU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aeluma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aeluma's regulatory disclosures and financial reporting.
Aeluma, Inc. insider Mark N. Tompkins reported two stock sales and is now a former 10% owner. On February 4, 2026, he sold 28,544 common shares at a weighted average price of $14.63, and another 5,956 shares at a weighted average price of $15.12.
Each reported price reflects multiple trades within disclosed ranges of $13.94–$14.91 and $14.94–$15.50. After these transactions, Tompkins beneficially owned 1,790,488 Aeluma common shares directly and no longer qualifies as a 10% beneficial owner.
Aeluma, Inc. filed a post-effective amendment on Form S-1/S-3 to register the resale of up to 14,011,726 shares of common stock held by various selling stockholders. These shares come from prior private placements in 2021 and 2023, a merger with Biond Photonics, pre-merger holders, placement agent warrants and shares underlying 2024 convertible notes.
The company is not selling any new shares in this offering and will not receive proceeds from stockholder resales, other than potential cash from the exercise of outstanding placement agent warrants. Aeluma’s common stock trades on Nasdaq under the symbol ALMU, with 18,049,306 shares outstanding as of January 31, 2026. The filing also consolidates three earlier S-1 registration statements into a single combined prospectus.
Aeluma, Inc. 10% owner Mark N. Tompkins reported multiple open‑market sales of common stock over several days. On 01/29/2026 and 01/30/2026 he sold shares at weighted average prices between $15.45 and $17.33 per share, followed by an additional sale on 02/02/2026 at a weighted average price of $15.74 per share. After these transactions, he directly beneficially owned 1,824,988 Aeluma common shares.
Aeluma, Inc. insider activity: Mark N. Tompkins, a 10% owner of Aeluma (ALMU), reported open‑market sales of a total of 105,000 shares of common stock over three days in January 2026. The trades occurred on January 20–22, 2026 at weighted average prices reported between $18.05 and $21.58 per share, with each price reflecting multiple individual transactions within the stated ranges. After these sales, Tompkins directly beneficially owned 1,919,988 shares of Aeluma common stock. The footnotes state that the reported prices are weighted averages and that more detailed breakdowns by individual execution price are available upon request.
Aeluma, Inc. reported the results of its 2025 Annual General Meeting of shareholders. The meeting had a quorum, with 9,892,101 shares of common stock present or represented by proxy, representing 55.4% of the voting power entitled to vote.
Shareholders re-elected Steven P. DenBaars and John Paglia to the Board of Directors by plurality of the votes cast. A second proposal also passed, receiving 9,822,341 votes For, 57,925 Against, and 11,835 Abstain. The filing notes that broker non-votes are included only for purposes of determining whether a quorum is present.
Aeluma, Inc. director Mark N. Tompkins reported open-market sales of Aeluma common stock in mid-December. On December 9, 2025, he sold 10,861 shares at a weighted average price of $16.39 and 19,139 shares at a weighted average price of $17.06. On December 10, 2025, he sold 20,000 shares at a weighted average price of $17.49.
After these transactions, Tompkins beneficially owns 2,169,988 shares of Aeluma common stock directly. Each reported price is a weighted average for multiple individual trades executed within stated price ranges on the respective dates.
Aeluma, Inc. has filed a resale prospectus covering up to 11,010,002 shares of its Common Stock, which may be sold from time to time by existing selling stockholders. The company’s shares trade on the Nasdaq Capital Market under the symbol ALMU, and Aeluma will not receive any proceeds from these stockholder sales, other than any cash received if placement agent warrants are exercised.
Aeluma develops high-performance optoelectronic devices and photodetector arrays using compound semiconductor materials on large-diameter silicon wafers for applications including 3D imaging, LiDAR, AR/VR, defense, aerospace and communications. The company has raised capital through recent underwritten offerings and note conversions and has secured U.S. government contracts with the Department of Energy, the U.S. Navy and NASA to advance shortwave infrared and quantum sensing technologies.
The prospectus highlights that Aeluma is an early-stage business, not yet in volume production, and faces risks common to speculative semiconductor ventures, including the need for additional capital, reliance on government and key customers, intense competition, regulatory complexity, and potential volatility in demand, supply chains and the broader chip industry.
Aeluma, Inc. has filed Post-Effective Amendment No. 6 to its Form S-1 to maintain the registration for the resale of up to 11,010,002 shares of common stock by selling stockholders. These shares include stock issued in prior offerings, merger-related share issuances, placement agent compensation and pre-merger holdings. The company will not receive proceeds from stockholder resales, other than potential cash from the future exercise of placement agent warrants, which could total up to $720,000.
Aeluma is an early-stage semiconductor company developing high-performance optoelectronic image sensors and photodetectors for applications such as 3D imaging, LiDAR, AR/VR, defense, aerospace and quantum systems. Recent financing activities include two 2025 underwritten offerings and conversion of $3.1 million of notes into equity, while a $100,000,000 shelf registration provides additional capital-raising flexibility. The company highlights multiple 2025 contracts with U.S. government agencies and emphasizes substantial risks typical of a young, unprofitable, R&D-intensive business operating in a cyclical, highly competitive semiconductor market.
Aeluma, Inc. has filed a prospectus supplement registering 2,017,498 shares of common stock and 85,653 shares of common stock underlying placement agent warrants. The supplement attaches the company’s latest quarterly report for the period ended September 30, 2025, giving investors updated financial and business information.
For the quarter, revenue rose to $1.4 million, up from $0.5 million a year earlier, mainly from government contracts, while the net loss widened to $1.5 million as the company increased spending on materials, staff, and stock-based compensation to support growth. Aeluma closed two public equity offerings in March and September 2025, boosting cash, cash equivalents, and a certificate of deposit to $38.1 million and alleviating previously disclosed substantial doubt about its ability to continue as a going concern. The company reports that its disclosure controls were not yet effective and is adding finance leadership and staff to improve internal controls.